Compare YPF & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | YPF | PCVX |
|---|---|---|
| Founded | 1977 | 2013 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Integrated oil Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1B | 6.0B |
| IPO Year | 1993 | 2020 |
| Metric | YPF | PCVX |
|---|---|---|
| Price | $35.84 | $47.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $41.67 | ★ $101.67 |
| AVG Volume (30 Days) | 1.2M | ★ 1.5M |
| Earning Date | 11-07-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $15,662,491,497.00 | N/A |
| Revenue This Year | $46.43 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 41.18 | N/A |
| 52 Week Low | $22.82 | $27.66 |
| 52 Week High | $47.43 | $93.77 |
| Indicator | YPF | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 52.81 | 55.07 |
| Support Level | $35.35 | $42.40 |
| Resistance Level | $36.57 | $48.65 |
| Average True Range (ATR) | 0.96 | 1.61 |
| MACD | -0.07 | 0.21 |
| Stochastic Oscillator | 73.46 | 74.74 |
YPF SA is an Argentina-based integrated oil and gas company. It is engaged in operating a fully integrated oil and gas chain across the domestic upstream, downstream, and gas and power segments. Its upstream segment consists of exploration, development, and production of crude oil, natural gas, and LPG. Its downstream segment include refining, marketing, transportation, and distribution of oil and a wide range of petroleum products, petroleum derivatives, petrochemicals, LPG and bio-fuels. Gas and Power segment performs activities related to natural gas transportation to third parties and Downstream segment. Central Administration and Others includes activities performed by the Group not falling under the business segments. It generates maximum revenue from downstream segment.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.